Bern, Switzerland, Thursday, January 26, 2023 - CIS Pharma attends the first Swiss RNA Therapeutics Summit in Bern. The Summit brings together stakeholders in the field of RNA Therapeutics [...]

Bubendorf, Switzerland, Wednesday, January 18, 2023 -  CIS Pharma has identified its lead anti-B7H3 nanobody displaying promising affinity to the target. The production of the final candidate is up-scaled [...]

Bubendorf, Switzerland, Tuesday, December 20, 2022 - CIS Pharma has successfully tested its anti-L1CAM radioligand against ovarian cancer in a Xenograft mouse model. The antibody-based radioligand comprises chelators conjugated [...]

Bubendorf, Switzerland, Thursday, December 8, 2022 - CIS Pharma has successfully tested its linker technology. The technology creates immuno-conjugates with higher uniformity and stability compared to immuno-conjugates based on [...]

Bubendorf, Switzerland, Wednesday, November 23, 2022 - CIS Pharma has successfully tested its anti-L1CAM ADC technology against triple-negative breast cancer, TNBC, in a Zebrafish tumor model. An ADC carrying [...]

Zurich, Switzerland, Tuesday, November 22, 2022 – CIS Pharma will attend the conference Clinical Operations in Oncology Trials Europe 2022. The conference offers insights and practical take-aways on successful [...]

Basel, Switzerland, Wednesday, November 2, 2022 – CIS Pharma will attend the Festival of Biologics, Europe’s most exciting biologic’s event, taking place in Basel. The team is looking forward [...]

Leipzig, Germany, Monday, October 24 - CIS Pharma will attend Bio- Europe, the gateway to the global biopharma community. The team is looking forward to an exciting programme including [...]

Barcelona, Spain, Saturday, October 15, 2022 – CIS Pharma will attend the 35th Annual Congress of the European Association of Nuclear Medicine in Barcelona. The team is looking forward [...]